Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding

被引:248
作者
Banker, MJ [1 ]
Clark, TH [1 ]
Williams, JA [1 ]
机构
[1] Pfizer Inc, Global Res & Dev, Pharmaceut R&D, Groton, CT 06340 USA
关键词
protein binding; equilibrium dialysis; high-throughput screening; volume shifts;
D O I
10.1002/jps.10332
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A 96-well equilibrium dialysis block was designed and constructed that is compatible with most standard 96-well format laboratory supplies and instruments. The unique design of the dialysis apparatus allows one to dispense and aspirate from either or both the sample and dialysate sides from the top of the apparatus, which is not possible with systems currently on the market. This feature permits the investigator to analyze a large number of samples, time points, or replicates in the same experiment. The novel alignment of the dialysis membrane vertically in the well maximizes the surface-to-volume ratio, eliminates problems associated with trapped air pockets, and allows one to add or remove samples independently or all at once. Furthermore, the design of the apparatus allows both the sample and dialysate sides of the dialysis well to be accessible by robotic systems, so assays can be readily automated. Teflon construction is used to minimize nonspecific binding of test samples to the apparatus. The device is reusable, easily assembled, and can be shaken in controlled temperature environments to decrease the time required to reach equilibrium as well as facilitate dissolution of test compounds. Plasma protein binding values obtained for 10 diverse compounds using standard dialysis equipment and the 96-well dialysis block validates this method. (C) 2003 Wiley-Liss, Inc. and the American Pharmaceutical Association.
引用
收藏
页码:967 / 974
页数:8
相关论文
共 37 条
[1]   CLINICAL PHARMACOKINETICS OF SULFONYLUREA HYPOGLYCEMIC DRUGS [J].
BALANT, L .
CLINICAL PHARMACOKINETICS, 1981, 6 (03) :215-241
[2]  
Bayliss M K, 1999, Curr Opin Drug Discov Devel, V2, P20
[3]   FLUID SHIFTS AND OTHER FACTORS AFFECTING PLASMA-PROTEIN BINDING OF PREDNISOLONE BY EQUILIBRIUM DIALYSIS [J].
BOUDINOT, FD ;
JUSKO, WJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (06) :774-780
[4]   DISPOSITION OF WARFARIN ENANTIOMERS AND METABOLITES IN PATIENTS DURING MULTIPLE DOSING WITH RAC-WARFARIN [J].
CHAN, E ;
MCLACHLAN, AJ ;
PEGG, M ;
MACKAY, AD ;
COLE, RB ;
ROWLAND, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) :563-569
[5]   AGE AND PROPRANOLOL STEREOSELECTIVE DISPOSITION IN HUMANS [J].
COLANGELO, PM ;
BLOUIN, RA ;
STEINMETZ, JE ;
MCNAMARA, PJ ;
DEMARIA, AN ;
WEDLUND, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (05) :489-494
[6]   THE BINDING OF KETAMINE TO PLASMA-PROTEINS - EMPHASIS ON HUMAN-PLASMA [J].
DAYTON, PG ;
STILLER, RL ;
COOK, DR ;
PEREL, JM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (06) :825-831
[7]   IMPORTANCE OF PROTEIN-BINDING FOR THE INTERPRETATION OF SERUM OR PLASMA DRUG CONCENTRATIONS [J].
GREENBLATT, DJ ;
SELLERS, EM ;
KOCHWESER, J .
JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (5-6) :259-263
[8]  
GREENBLATT DJ, 1980, CLIN PHARMACOL THER, V26, P291
[9]  
GUSTAVSON LE, 1985, BUTTERWORTHS INT MED, V4, P234
[10]   DRUG-BINDING IN PLASMA - A SUMMARY OF RECENT TRENDS IN THE STUDY OF DRUG AND HORMONE-BINDING [J].
HERVE, F ;
URIEN, S ;
ALBENGRES, E ;
DUCHE, JC ;
TILLEMENT, JP .
CLINICAL PHARMACOKINETICS, 1994, 26 (01) :44-58